Alexis E. Cullen

Alexis E. Cullen

Senior Forskare
E-postadress: alexis.cullen@ki.se
Besöksadress: Avd försäkringsmedicin, Karolinska Institutet, 17177 Stockholm
Postadress: K8 Klinisk neurovetenskap, K8 Fm Mittendorfer-Rutz, 171 77 Stockholm

Om mig

  • Dr Alexis E. Cullen är huvudforskare inom psykiatrisk epidemiologi vid Avdelningen för försäkringsmedicin på Karolinska Institutet. Hennes främsta forskningsintressen omfattar psykotiska störningar, reproduktiv psykiatri och barnpsykopatologi. Dr Cullens forskning syftar i första hand till att belysa etiologin bakom psykotiska störningar, med särskilt fokus på tidiga upptäcktsstrategier samt stressens och könshormonernas betydelse. Hon leder för närvarande tvärvetenskapliga forskningsprojekt som spänner över flera metodologier, inklusive registerbaserade studier, longitudinella kohorter och evidenssyntesprojekt.

    UTBILDNING
    • PhD i utvecklingspsykopatologi (10/2009 – 05/2014), Institute of Psychiatry, Psychology & Neuroscience, King’s College London, Storbritannien
    • MSc i rättspsykiatrisk forskningsmetodik (09/2006 – 09/2008), Institute of Psychiatry, Psychology & Neuroscience, King’s College London, Storbritannien
    • BSc med dubbel huvudämnesexamen i psykologi och biologi (10/2003 – 07/2006), University of Reading, Storbritannien

Undervisning

  • Dr Cullen bidrar med undervisning och handledning av studenter på masterprogrammet i folkhälsovetenskap och masterprogrammet i global hälsa vid Karolinska Institutet.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Tidstrender och ojämlikhet i diagnos, yrkesmässig börda och behandling av tillstånd i klimakteriet och förklimakteriet
    Forte
    1 January 2026 - 31 December 2028
  • Utveckling av Preventiv Psykiatri i Sverige: Utvärdering och Klinisk Implementering av Digitala Verktyg för Tidig Upptäckt av Psykos samt Suicidrisk Vid Svår Psykisk Ohälsa
    Forte
    1 July 2025 - 30 June 2029
  • Swedish Research Council
    1 December 2023 - 30 November 2026
    Exhaustion disorder (ED, utmattningssyndrom) is one of the most common and costly mental disorders in Swedish primary care. However, the validity of ED is debated and there are no evidence-based treatments. The core of ED - fatigue - is common across a range of disorders. Recent advances in international research indicate that fatigue is best understood as a transdiagnostic symptom dimension rather than a diagnosis-specific pathology. This paves the way for new, potentially more effective, approaches to assessment and treatment.The purpose of this project is to increase knowledge of fatigue as a transdiagnostic symptom in primary care patients and to build evidence for a highly accessible transdiagnostic treatment for fatigue. Consecutively recruited primary care patients (N=500) with fatigue will be included in a multicenter randomized controlled trial and receive internet-delivered transdiagnostic cognitive behavioral therapy adjunct to care as usual, or care as usual only. Primary outcome will be change in fatigue severity (pre-post treatment) with controlled follow-ups up to 2 years from baseline. Moderators and mechanisms of treatment effect, and cost-effectiveness, will be analyzed.This project has the potential to build solid evidence for an accessible, cost-effective treatment of fatigue that can be readily implemented in primary care. Results will contribute to development of guidelines for assessment and treatment of fatigue, and better use of healthcare resources.
  • Swedish Research Council for Health Working Life and Welfare
    1 December 2023 - 30 November 2026
    Research problem and specific questionsExhaustion disorder (ED, utmattningssyndrom) is one of the most common and costly mental disorders in Sweden, but the validity of ED is debated and there are no evidence-based treatments. The core of ED - fatigue - is common across a range of disorders, associated with work-disability and excess mortality. There is mounting evidence from international research supporting that fatigue should be conceptualized as a transdiagnostic symptom dimension rather than a diagnosis-specific pathology. Cognitive behavioral therapy (CBT) is effective in reducing fatigue across a range of medical conditions by the same change mechanisms. This speaks for a transdiagnostic treatment approach. The purpose of this project is to increase knowledge of fatigue as a transdiagnostic symptom in primary care patients and to evaluate the effect of a highly accessible transdiagnostic CBT for fatigue on symptom reduction and long-term work disability. We also aim to investigate moderators and mediators of treatment effect and treatment cost-effectiveness.Data and method Consecutively recruited primary care patients (N=500) with fatigue (independent of primary diagnosis) will be included in a multicenter randomized clinical trial and receive internet-delivered transdiagnostic CBT adjunct to care as usual, or care as usual only. Primary outcome will be change in fatigue severity (pre-post treatment). Secondary outcomes include self-rated symptoms, functional ability, and objective measures of cognitive impairment. Registry data will be used for analysis of healthcare consumption and sickness absence to the 1-year follow-up. Societal relevance and utilization  Fatigue is associated with suffering, work-disability, and high societal costs. This project can build solid evidence for an accessible, cost-effective treatment for fatigue with the potential to improve functional ability and prevent long-term sickness absence. Results can contribute to development of guidelines for assessment and treatment of fatigue, evidence-based recommendations for sick-leave prescription, and more efficient use of healthcare resources.Plan for project realization:Patients will be recruited from at least 3 primary care centers in Stockholm, using existing infrasturctures for care. The project group is a multidisciplinary team of researchers and clinicians from Karolinska Institutet, Stockholm University, and Amsterdam University Medical Center, Netherlands.
  • Developing mobile digital technologies to measure stress-biomarker signatures across psychotic illness stages
    Brain & Behavior Research Foundation
    1 January 2020 - 31 December 2021
  • Biological markers of stress and inflammation across clinical stages of schizophrenia: from early at-risk states to chronic illness.
    Wellcome Trust Ltd
    1 November 2015 - 31 October 2019
  • Does elevated C-reactive protein predict future psychopathology amongst children exposed to trauma?
    The Waterloo Foundation
    1 March 2013 - 28 February 2014
  • Investigating the Effect of the Menstrual Cycle on Social Stress in Early Psychosis Through Ecological Momentary Assessment
    Medical Research Council

Nyheter från KI

Kalenderhändelser från KI